Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Quinoline tryptamine heterozygote and application thereof in preparation of medicines for treating Alzheimer's disease

A drug and pharmaceutical technology, applied in the field of medicine, can solve the problems of no breakthrough progress, no successful launch of new drugs, difficult disease treatment, etc. Effect of ion chelating ability

Inactive Publication Date: 2020-09-22
SUN YAT SEN UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, the development of anti-AD drugs aimed at inhibiting Aβ aggregation or clearing senile plaques formed by Aβ aggregation, or targeting other single targets, has been a hot spot in this field, but so far, no breakthroughs have been made. No new drug successfully marketed
[0004] In view of the complex pathogenesis of AD, the etiological mechanism has not been fully elucidated, and the various mechanisms are interconnected and affect each other, which brings great difficulties to the treatment of the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinoline tryptamine heterozygote and application thereof in preparation of medicines for treating Alzheimer's disease
  • Quinoline tryptamine heterozygote and application thereof in preparation of medicines for treating Alzheimer's disease
  • Quinoline tryptamine heterozygote and application thereof in preparation of medicines for treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] The synthesis of embodiment 1 8-hydroxyquinoline-2-formaldehyde

[0078]

[0079] SeO 2 (2.22g, 20mmol) was added to 1,4-dioxane solution (50mL), and an aqueous solution (0.7mL) was added, heated to 60°C so that SeO 2 After complete dissolution, a solution of 2-methyl-8-hydroxyquinoline (1.59 g, 10 mmol) in 1,4-dioxane (10 mL) was added dropwise within half an hour. Heat to reflux until the reaction is complete. Suction filtration, vacuum drying, and purification by column chromatography yielded 1.48 g of a pale yellow solid. Yield 86%.

[0080] 1 H NMR (400MHz, (CD 3 ) 2CO)δ10.16(s,1H),9.22(s,1H),8.55(d,J=8.5Hz,1H),8.04(d,J=8.5Hz,1H),7.69(t,J=8.0Hz ,1H),7.57(dd,J=8.2,0.9Hz,1H),7.28(dd,J=7.7,1.0Hz,1H).

Embodiment 2

[0081] Example 2 8-hydroxyquinoline-2-carboxylic acid

[0082]

[0083] SeO 2 (2.22g, 20mmol) was added into pyridine (20mL), and after heating to 60°C, 2-methyl-8-hydroxyquinoline (3.18g, 20mmol) was added. After the addition is complete, stir at 120°C until the reaction is complete. After vacuum-filtering, it was dissolved in aqueous KOH (10%) and the residual solid was filtered off. The filtered liquid was acidified with aqueous hydrochloric acid (10%). After suction filtration, 1.891 g of red solid was obtained. Yield 50%.

[0084] 1 H NMR (400MHz, (CD 3 ) 2 CO)δ9.68(s,1H),8.63(d,J=8.5Hz,1H),8.27(d,J=8.5Hz,1H),7.70(t,J=7.9Hz,1H),7.60(d ,J=8.2Hz,1H),7.28(d,J=7.6Hz,1H).

Embodiment 3

[0085] Example 3 5-(chloromethyl)quinolin-8-ol hydrochloride

[0086]

[0087] 8-Hydroxyquinoline (5.84 g, 40.2 mmol) was added to 70 mL of concentrated hydrochloric acid, and 6.4 mL of formaldehyde (37%) solution was added along with a catalytic amount of zinc chloride (0.6 g). After stirring overnight at room temperature, the mixture was filtered, washed with copious amounts of acetone and dried. 7.86 g of a yellow solid was obtained with a yield of 85%.

[0088] 1 H NMR (400MHz, DMSO-d 6 )δ9.22(d, J=7.9Hz, 1H), 9.13(dd, J=5.0, 1.1Hz, 1H), 8.12(dd, J=8.6, 5.1Hz, 1H), 7.87(d, J=8.0 Hz,1H),7.51(d,J=8.0Hz,1H),5.33(s,2H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a quinoline tryptamine heterozygote and application thereof in preparation of medicines for treating and / or preventing Alzheimer's disease. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The quinoline tryptamine heterozygote disclosed by the invention has excellent oxygen free radical scavenging capacity, a protective effect on hydrogen peroxide induced SH-SY5Y cell oxidative damage, good blood-brain barrier passive dialysis capacity, an A[beta] self-aggregation inhibiting effect and metal ion chelating capacity, and is a multi-target anti-Alzheimer disease active molecule. The compound is expected to be used as a clinical medicine for treating and / or preventing Alzheimer's disease.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a quinoline tryptamine hybrid and its application in the preparation of medicines for treating and / or preventing Alzheimer's disease. Background technique [0002] Alzheimer's Disease (AD), also known as Alzheimer's disease, is an age-related degenerative disease of the central nervous system. The disease was first discovered by German psychiatrist Alois Alzheimer in 1906, more than 100 years ago. The research results show that the neuropathological features of AD are mainly neurofibrillary tangles (neurofibrillary tangles, NFTs) in nerve cells formed by abnormal aggregation of tau protein hyperphosphorylation and senile plaques formed by β-amyloid deposition outside the cells ( senile plaques, SPs), accompanied by cerebral vascular changes and granular vacuolar degeneration. Clinically, the patients gradually develop memory impairment, executive dysfunction, aphas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/12A61K31/4709A61P25/28A61P39/06A61P39/04A61P43/00
CPCA61P25/28A61P39/04A61P39/06A61P43/00C07D401/12
Inventor 黄玲潘廷婷周彦黎兴术
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com